3-(4-(phenylethynyl)phenyl)propanoic acid | 1082058-90-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(4-(phenylethynyl)phenyl)propanoic acid
• 英文别名: 3-(4-(phenylethynyl)phenyl)propionic acid；3-[4-(2-phenylethynyl)phenyl]propanoic acid
• CAS: 1082058-90-9
• 化学式: C₁₇H₁₄O₂
• 分子量: 250.297
• InChiKey: ZOWBFTGCXGCEGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-二甲氧基-5-甲基-1,4-苯醌 、 3-(4-(phenylethynyl)phenyl)propanoic acid 在 dipotassium peroxodisulfate 、 silver nitrate 作用下， 以 水 、 乙腈 为溶剂， 反应 1.0h， 以9%的产率得到
  参考文献：
  名称：

  Alkyne-Tag Raman Imaging for Visualization of Mobile Small Molecules in Live Cells

  摘要：

  Alkyne has a unique Raman band that does not overlap with Raman scattering from any endogenous molecule in live cells. Here, we show that alkyne-tag Raman imaging (ATRI) is a promising approach for visualizing nonimmobilized small molecules in live cells. An examination of structure Raman shift/intensity relationships revealed that alkynes conjugated to an aromatic ring and/or to a second allcyne (conjugated diynes) have strong Raman signals in the cellular silent region and can be excellent tags. Using these design guidelines, we synthesized and imaged a series of alkyne-tagged coenzyme Q (CoQ) analogues in live cells. Cellular concentrations of diyne-tagged Coganalogues could be semiquantitatively estimated. Finally, simultaneous imaging of two small molecules, 5-ethynyl-2 '-deoxyuridine (EdU) and a Cog analogue, with distinct Raman tags was demonstrated.

  DOI：

  10.1021/ja308529n
• 作为产物：
  描述：

  3-(4-溴苯基)丙酸 在 copper(l) iodide 、 四(三苯基膦)钯 、 potassium carbonate 、 三乙胺 、 乙酰氯 、 lithium hydroxide 、 三甲基乙炔基硅 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 生成 3-(4-(phenylethynyl)phenyl)propanoic acid
  参考文献：
  名称：

  通过 Tolane 修饰的肽核酸鉴别 SNP：在病原体耐药性检测中的应用

  摘要：

  在治疗病毒或细菌感染期间，重要的是评估对所用治疗剂的任何耐药性。由特定基因中的单个碱基突变引起的氨基酸取代通常会导致病原体产生耐药性。因此，需要区分目标序列中单个碱基错配的分子工具来实现治疗成功。在这里，我们通过 N 末端的酰胺键合成了由 tolane 衍生的肽核酸 (PNA)，并成功地提高了序列特异性，即使在双链末端区域附近存在错配的碱基对也是如此。我们通过紫外线熔化温度分析、热力学分析、计算机构象搜索和凝胶迁移率变化测定评估了 tolane-PNA 对单链 DNA 和 RNA 的序列特异性。结果，所有 PNA-tolane 衍生物都稳定了与匹配目标序列的双链体形成，而不会导致错配目标结合。在不同的 PNA-tolane 衍生物中，用萘基型 tolane 修饰的 PNA 可以有效区分错配的碱基对，并用于检测甲型 H1N1 流感病毒对神经氨酸酶抑制剂的耐药性。因此，我们的分子工具可用于区分

  DOI：

  10.3390/molecules25040769

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：UNIV SYDDANSK

  公开号：WO2010012650A1

  公开（公告）日：2010-02-04

  There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type Il diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.

  提供了一种新型化合物，能够调节G蛋白偶联受体GPR40，包括该化合物的组合物和使用方法，用于控制体内胰岛素水平，治疗II型糖尿病、高血压、酮症、肥胖症、葡萄糖不耐受症和与异常高或低血浆脂蛋白、甘油三酯或葡萄糖水平相关的相关疾病。
• COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES
  申请人：Ulven Trond

  公开号：US20110152315A1

  公开（公告）日：2011-06-23

  There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type I1 diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.

  提供了一种新的化合物，能够调节G蛋白偶联受体GPR40，包括该化合物的组合物以及使用它们的方法，用于控制体内胰岛素水平和治疗诸如2型糖尿病、高血压、酮症酸中毒、肥胖症、葡萄糖耐受性不良以及与异常高或低血浆脂蛋白、甘油三酯或葡萄糖水平有关的相关疾病。
• Tolan compound
  申请人：OSAKA UNIVERSITY

  公开号：US10577396B2

  公开（公告）日：2020-03-03

  An object of the present invention is to conduct a search for a compound to be arranged at a terminal of a peptide nucleic acid effective in detecting a single nucleotide polymorphism. Provided is a tolan compound represented by the following formula (1): wherein R1 represents a phenyl group or a naphthyl group, the phenyl group may have 1 to 5 substituents that are identical to or different from each other, and the naphthyl group may have 1 to 7 substituents that are identical to or different from each other.

  本发明的目的是寻找一种化合物，将其排列在肽核酸的末端，可有效地检测单核苷酸多态性。本发明提供了一种由下式（1）表示的托兰化合物： 其中 R1 代表苯基或萘基，苯基可以有 1 至 5 个彼此相同或不同的取代基，萘基可以有 1 至 7 个彼此相同或不同的取代基。
• Discovery of Potent and Selective Agonists for the Free Fatty Acid Receptor 1 (FFA₁/GPR40), a Potential Target for the Treatment of Type II Diabetes
  作者：Elisabeth Christiansen、Christian Urban、Nicole Merten、Kathrin Liebscher、Kasper K. Karlsen、Alexandra Hamacher、Andreas Spinrath、Andrew D. Bond、Christel Drewke、Susanne Ullrich、Matthias U. Kassack、Evi Kostenis、Trond Ulven

  DOI：10.1021/jm8010178

  日期：2008.11.27

  A series of 4-phenethynyldihydrocinnamic acid agonists of the free fatty acid receptor 1 (FFA(1)) has been discovered and explored. The preferred compound 20 (TUG-424, EC50 = 32 nM) significantly increased glucose-stimulated insulin secretion at 100 nM and may serve to explore the role of FFA(1) in metabolic diseases such as diabetes or obesity.
• TOLAN COMPOUND
  申请人：OSAKA UNIVERSITY

  公开号：US20180258141A1

  公开（公告）日：2018-09-13

  An object of the present invention is to conduct a search for a compound to be arranged at a terminal of a peptide nucleic acid effective in detecting a single nucleotide polymorphism. Provided is a tolan compound represented by the following formula (1): wherein R 1 represents a phenyl group or a naphthyl group, the phenyl group may have 1 to 5 substituents that are identical to or different from each other, and the naphthyl group may have 1 to 7 substituents that are identical to or different from each other.